528 results on '"Zaanan, Aziz"'
Search Results
2. Peritoneal Tumour DNA in Peritoneal Fluid: Emerging Tool for Peritoneal Metastasis Detection
3. Is laparoscopic approach as treatment of large gastric GIST acceptable?
4. Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases
5. Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial
6. A systematic review of minimal length of lroximal margin in gastric adenocarcinoma resection
7. Biomarkers for Immunotherapy in Gastrointestinal Cancers
8. New developments and standard of care in the management of advanced gastric cancer
9. Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study
10. Treatment of gastric adenocarcinoma: A rapidly evolving landscape
11. Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study
12. Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives
13. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency
14. Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability
15. MSI colorectal cancer, all you need to know
16. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial
17. Immunothérapie dans le traitement du cancer gastrique métastatique
18. L'immunothérapie : une des avancées majeures de cette dernière décennie dans le traitement des cancers digestifs.
19. Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort
20. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
21. Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey
22. Prognostic factors of colorectal cancer patients with brain metastases
23. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
24. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
25. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials
26. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)
27. Personalized four-category staging for predicting prognosis in patients with small bowel Adenocarcinoma: an international development and validation study
28. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study
29. Drastic decrease of urgent endoscopies outside regular working hours during the Covid-19 pandemic in the paris area
30. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
31. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review
32. Patients atteints d’un cancer gastrique localisé MSI/dMMR, pas de chimiothérapie mais une immunothérapie périopératoire : l’essai de phase II GERCOR NEONIPIGA vient d’être ouvert au recrutement
33. Pembrolizumab en association à la chimiothérapie de première ligne du traitement des adénocarcinomes gastriques ou de la jonction œsogastrique, HER2 négatifs, localement avancés non résécables ou métastatiques
34. Detection of Microsatellite Instability in Colorectal Cancer Tissue and Plasma samples using a new Multiplex Droplet Digital PCR kit
35. An ileo-anal pouch doing the twist (with video)
36. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency
37. High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer
38. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
39. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations
40. Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: A population-based cohort and international multicentre cohort study
41. FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
42. Valeur prédictive et pronostique du phénotype MSI dans le cancer du colon non métastatique : qui et comment traiter ?
43. Biomarkers for Immunotherapy in Gastrointestinal Cancers
44. Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)
45. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer
46. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)
47. Exploring the best treatment options for BRAF-mutant metastatic colon cancer
48. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
49. A fatal case of 5-FU toxicity despite dose adjustment in a patient with a partial DPD deficiency receiving the FLOT regimen
50. Tislelizumab en deuxième ligne de traitement du carcinome épidermoïde avancé de l’œsophage après échec des sels de platine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.